BioSpace News Archive

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today it will acquire Baystate Health, Inc.'s (Baystate Health) outreach laboratory business and select operating assets, including laboratory service centers operated by Baystate Health throughout Massachusetts.

Board of Directors approves quarterly cash dividend of $0.41 per share Pfizer Inc. announced that its board of directors declared a $0.41 fourth-quarter 2023 dividend on the company’s common stock, payable December 4, 2023, to holders of the Common Stock of record at the close of business on November 10, 2023.

Nortech Systems Incorporated is proud to announce that its Suzhou, China facility has been certified by the National Medical Products Administration to produce Class II Medical Devices for customers in Asia.

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced an oral presentation at the Foundation for Prader-Willi Research 2023 Research Symposium, being held October 5-6, 2023, in Denver, Colorado.

MyMD Pharmaceuticals, Inc. ® announced that it plans to share information on the Company and its product pipeline, including an update on recent positive phase 2 study results for MYMD-1 in sarcopenia, at the upcoming BioFuture 2023 Meeting.

Araris Biotech AG (“Araris”), a company developing ADCs using its proprietary linker-payload technology, today announced the appointment of Dragan Grabulovski, Ph.D., to acting chief executive officer (CEO).

Keros Therapeutics, Inc. today announced results from preclinical studies evaluating the treatment effect of a research form of KER-065 (“RKER-065”) in a mouse model of Duchenne muscular dystrophy (“DMD”) and in prednisolone-treated mice, which were presented at the 28th International Annual Congress of the World Muscle Society (“WMS”) on Wednesday, October 4, 2023.

Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2023 financial results on Wednesday, October 25, 2023, prior to the market open.

Foghorn ® Therapeutics Inc. today announced that new clinical and pre-clinical data for its BRG1/BRM inhibitor FHD-286, pre-clinical data for its selective EP300 program, and pre-clinical data for its BRD9 degrader FHD-609, will be presented at the AACR-NCI-EORTC International Conference.

Akero Therapeutics, Inc. today announced publication in The Lancet Gastroenterology & Hepatology of results from the HARMONY Phase 2b trial in nonalcoholic steatohepatitis (NASH).